Evaluation Drug Related Problems (DRPS) in Cervical Cancer Patients Undergoing Chemotherapy in Inpatient Care at Dr. M. Yunus Regional Hospital Bengkulu City

Cervical cancer requires complex treatment, including chemotherapy, which may cause Drug-Related Problems (DRPs) affecting therapeutic safety and effectiveness. This study aimed to identify patient characteristics, chemotherapy drug usage profiles, and DRP incidence according to the Pharmaceutical Care Network Europe (PCNE) Version 9.01 at Dr. M. Yunus Regional General Hospital, Bengkulu City. A descriptive observational study with a retrospective approach was conducted using medical records of cervical cancer patients receiving chemotherapy between 2023 and 2025. Purposive sampling selected 61 patients with 98 chemotherapy visits based on the inclusion criteria. Data were analyzed descriptively. All patients were female, with the largest age group being 46–55 years (22 patients; 36.1%). Paclitaxel and carboplatin were used in all chemotherapy visits. The evaluation identified 19 DRP instances across 98 visits, equivalent to 19.39 DRPs per 100 visits. The identified problems comprised doses that were too low (8 cases; 42.11%), doses that were too high (6 cases; 31.58%), and inappropriate drug selection, dosage strength, or recommended dosage (5 cases; 26.31%). No other DRP categories were identified. Dosage-related problems represented the most frequent DRPs among cervical cancer patients undergoing chemotherapy. These findings highlight the importance of evaluating medication regimens in relation to patients’ clinical conditions and treatment documentation. The results may support physicians and pharmacists in verifying dosages, optimizing therapeutic monitoring, and improving medication use accuracy to enhance treatment safety and effectiveness.